<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:59:04 -0700</creation_date>
  <update_date>2013-01-15 18:59:04 -0700</update_date>
  <accession>HMDBP01738</accession>
  <secondary_accessions>
    <accession>7087</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>BK channel</synonym>
    <synonym>BKCA alpha</synonym>
    <synonym>Calcium-activated potassium channel, subfamily M subunit alpha-1</synonym>
    <synonym>K(VCA)alpha</synonym>
    <synonym>KCa1.1</synonym>
    <synonym>Maxi K channel</synonym>
    <synonym>MaxiK</synonym>
    <synonym>Slo homolog</synonym>
    <synonym>Slo-alpha</synonym>
    <synonym>Slo1</synonym>
    <synonym>Slowpoke homolog</synonym>
    <synonym>hSlo</synonym>
  </synonyms>
  <gene_name>KCNMA1</gene_name>
  <general_function>Involved in ion channel activity</general_function>
  <specific_function>Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX)</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03178</accession>
      <name>Heme</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01361</accession>
      <name>Carbon monoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00586</accession>
      <name>Potassium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01928</accession>
      <name>Hydrochlorothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14373</accession>
      <name>Enflurane</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14500</accession>
      <name>Chlorzoxazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14580</accession>
      <name>Bendroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14912</accession>
      <name>Hydroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15138</accession>
      <name>Cromoglicic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15242</accession>
      <name>Miconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15251</accession>
      <name>Diazoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14118</accession>
      <name>Trifluoroacetic acid</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>calcium activated cation channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>calcium-activated potassium channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>potassium channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>voltage-gated potassium channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cation transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>monovalent inorganic cation transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>potassium ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>macromolecular complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>protein complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>ion channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cation channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>potassium channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>voltage-gated potassium channel complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>10q22.3</locus>
    <gene_sequence>&gt;3711 bp
ATGGCAAATGGTGGCGGCGGCGGCGGCGGCAGCAGCGGCGGCGGCGGCGGCGGCGGAGGC
AGCAGTCTTAGAATGAGTAGCAATATCCACGCGAACCATCTCAGCCTAGACGCGTCCTCC
TCCTCCTCCTCCTCCTCTTCCTCTTCTTCTTCTTCCTCCTCCTCTTCCTCCTCGTCCTCG
GTCCACGAGCCCAAGATGGATGCGCTCATCATCCCGGTGACCATGGAGGTGCCGTGCGAC
AGCCGGGGCCAACGCATGTGGTGGGCTTTCCTGGCCTCCTCCATGGTGACTTTCTTCGGG
GGCCTCTTCATCATCTTGCTCTGGCGGACGCTCAAGTACCTGTGGACCGTGTGCTGCCAC
TGCGGGGGCAAGACGAAGGAGGCCCAGAAGATTAACAATGGCTCAAGCCAGGCGGATGGC
ACTCTCAAACCAGTGGATGAAAAAGAGGAGGCAGTGGCCGCCGAGGTCGGCTGGATGACC
TCCGTGAAGGACTGGGCGGGGGTGATGATATCCGCCCAGACACTGACTGGCAGAGTCCTG
GTTGTCTTAGTCTTTGCTCTCAGCATCGGTGCACTTGTAATATACTTCATAGATTCATCA
AACCCAATAGAATCCTGCCAGAATTTCTACAAAGATTTCACATTACAGATCGACATGGCT
TTCAACGTGTTCTTCCTTCTCTACTTCGGCTTGCGGTTTATTGCAGCCAACGATAAATTG
TGGTTCTGGCTGGAAGTGAACTCTGTAGTGGATTTCTTCACGGTGCCCCCCGTGTTTGTG
TCTGTGTACTTAAACAGAAGTTGGCTTGGTTTGAGATTTTTAAGAGCTCTGAGACTGATA
CAGTTTTCAGAAATTTTGCAGTTTCTGAATATTCTTAAAACAAGTAATTCCATCAAGCTG
GTGAATCTGCTCTCCATATTTATCAGCACGTGGCTGACTGCAGCCGGGTTCATCCATTTG
GTGGAGAATTCAGGGGACCCATGGGAAAATTTCCAAAACAACCAGGCTCTCACCTACTGG
GAATGTGTCTATTTACTCATGGTCACAATGTCCACCGTTGGTTATGGGGATGTTTATGCA
AAAACCACACTTGGGCGCCTCTTCATGGTCTTCTTCATCCTCGGGGGACTGGCCATGTTT
GCCAGCTACGTCCCTGAAATCATAGAGTTAATAGGAAACCGCAAGAAATACGGGGGCTCC
TATAGTGCGGTTAGTGGAAGAAAGCACATTGTGGTCTGCGGACACATCACTCTGGAGAGT
GTTTCCAACTTCCTGAAGGACTTTCTGCACAAGGACCGGGATGACGTCAATGTGGAGATC
GTTTTTCTTCACAACATCTCCCCCAACCTGGAGCTTGAAGCTCTGTTCAAACGACATTTT
ACTCAGGTGGAATTTTATCAGGGTTCCGTCCTCAATCCACATGATCTTGCAAGAGTCAAG
ATAGAGTCAGCAGATGCATGCCTGATCCTTGCCAACAAGTACTGCGCTGACCCGGATGCG
GAGGATGCCTCGAATATCATGAGAGTAATCTCCATAAAGAACTACCATCCGAAGATAAGA
ATCATCACTCAAATGCTGCAGTATCACAACAAGGCCCATCTGCTAAACATCCCGAGCTGG
AATTGGAAAGAAGGTGATGACGCAATCTGCCTCGCAGAGTTGAAGTTGGGCTTCATAGCC
CAGAGCTGCCTGGCTCAAGGCCTCTCCACCATGCTTGCCAACCTCTTCTCCATGAGGTCA
TTCATAAAGATTGAGGAAGACACATGGCAGAAATACTACTTGGAAGGAGTCTCAAATGAA
ATGTACACAGAATATCTCTCCAGTGCCTTCGTGGGTCTGTCCTTCCCTACTGTTTGTGAG
CTGTGTTTTGTGAAGCTCAAGCTCCTAATGATAGCCATTGAGTACAAGTCTGCCAACCGA
GAGAGCCGTATATTAATTAATCCTGGAAACCATCTTAAGATCCAAGAAGGTACTTTAGGA
TTTTTCATCGCAAGTGATGCCAAAGAAGTTAAAAGGGCATTTTTTTACTGCAAGGCCTGT
CATGATGACATCACAGATCCCAAAAGAATAAAAAAATGTGGCTGCAAACGGCCCAAGATG
TCCATCTACAAGAGAATGAGACGGGCATGTTGTTTTGATTGCGGACGTTCTGAGCGTGAC
TGCTCATGCATGTCAGGCCGTGTGCGTGGTAACGTGGACACCCTTGAGAGAGCCTTCCCA
CTTTCTTCTGTCTCTGTTAATGATTGCTCCACCAGTTTCCGTGCCTTTGAAGATGAGCAG
CCGTCAACACTATCACCAAAAAAAAAGCAACGGAATGGAGGCATGCGGAACTCACCCAAC
ACCTCGCCTAAGCTGATGAGGCATGACCCCTTGTTAATTCCTGGCAATGATCAGATTGAC
AACATGGACTCCAATGTGAAGAAGTACGACTCTACTGGGATGTTTCACTGGTGTGCACCC
AAGGAGATAGAGAAAGTCATCCTGACTCGAAGTGAAGCTGCCATGACCGTCCTGAGTGGC
CATGTCGTGGTCTGCATCTTTGGCGACGTCAGCTCAGCCCTGATCGGCCTCCGGAACCTG
GTGATGCCGCTCCGTGCCAGCAACTTTCATTACCATGAGCTCAAGCACATTGTGTTTGTG
GGCTCTATTGAGTACCTCAAGCGGGAATGGGAGACGCTTCATAACTTCCCCAAAGTGTCC
ATATTGCCTGGTACGCCATTAAGTCGGGCTGATTTAAGGGCTGTCAACATCAACCTCTGT
GACATGTGCGTTATCCTGTCAGCCAATCAGAATAATATTGATGATACTTCGCTGCAGGAC
AAGGAATGCATCTTGGCGTCACTCAACATCAAATCTATGCAGTTTGATGACAGCATCGGA
GTCTTGCAGGCTAATTCCCAAGGGTTCACACCTCCAGGAATGGATAGATCCTCTCCAGAT
AACAGCCCAGTGCACGGGATGTTACGTCAACCATCCATCACAACTGGGGTCAACATCCCC
ATCATCACTGAACTAGTGAACGATACTAATGTTCAGTTTTTGGACCAAGACGATGATGAT
GACCCTGATACAGAACTGTACCTCACGCAGCCCTTTGCCTGTGGGACAGCATTTGCCGTC
AGTGTCCTGGACTCACTCATGAGCGCGACGTACTTCAATGACAATATCCTCACCCTGATA
CGGACCCTGGTGACCGGAGGAGCCACGCCGGAGCTGGAGGCTCTGATTGCTGAGGAAAAC
GCCCTTAGAGGTGGCTACAGCACCCCGCAGACACTGGCCAATAGGGACCGCTGCCGCGTG
GCCCAGTTAGCTCTGCTCGATGGGCCATTTGCGGACTTAGGGGATGGTGGTTGTTATGGT
GATCTGTTCTGCAAAGCTCTGAAAACATATAATATGCTTTGTTTTGGAATTTACCGGCTG
AGAGATGCTCACCTCAGCACCCCCAGTCAGTGCACAAAGAGGTATGTCATCACCAACCCG
CCCTATGAGTTTGAGCTCGTGCCGACGGACCTGATCTTCTGCTTAATGCAGTTTGACCAC
AATGCCGGCCAGTCCCGGGCCAGCCTGTCCCATTCCTCCCACTCGTCGCAGTCCTCCAGC
AAGAAGAGCTCCTCTGTTCACTCCATCCCATCCACAGCAAACCGACAGAACCGGCCCAAG
TCCAGGGAGTCCCGGGACAAACAGAAGTACGTGCAGGAAGAGCGGCTTTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>1236</residue_number>
    <molecular_weight>137558.1</molecular_weight>
    <theoretical_pi>7.07</theoretical_pi>
    <pfams>
      <pfam>
        <name>BK_channel_a</name>
        <pfam_id>PF03493</pfam_id>
      </pfam>
      <pfam>
        <name>Ion_trans</name>
        <pfam_id>PF00520</pfam_id>
      </pfam>
      <pfam>
        <name>TrkA_N</name>
        <pfam_id>PF02254</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>87-107</region>
      <region>179-199</region>
      <region>215-235</region>
      <region>240-260</region>
      <region>265-285</region>
      <region>301-321</region>
      <region>368-388</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Calcium-activated potassium channel subunit alpha-1
MANGGGGGGGSSGGGGGGGGSSLRMSSNIHANHLSLDASSSSSSSSSSSSSSSSSSSSSS
VHEPKMDALIIPVTMEVPCDSRGQRMWWAFLASSMVTFFGGLFIILLWRTLKYLWTVCCH
CGGKTKEAQKINNGSSQADGTLKPVDEKEEAVAAEVGWMTSVKDWAGVMISAQTLTGRVL
VVLVFALSIGALVIYFIDSSNPIESCQNFYKDFTLQIDMAFNVFFLLYFGLRFIAANDKL
WFWLEVNSVVDFFTVPPVFVSVYLNRSWLGLRFLRALRLIQFSEILQFLNILKTSNSIKL
VNLLSIFISTWLTAAGFIHLVENSGDPWENFQNNQALTYWECVYLLMVTMSTVGYGDVYA
KTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRKKYGGSYSAVSGRKHIVVCGHITLES
VSNFLKDFLHKDRDDVNVEIVFLHNISPNLELEALFKRHFTQVEFYQGSVLNPHDLARVK
IESADACLILANKYCADPDAEDASNIMRVISIKNYHPKIRIITQMLQYHNKAHLLNIPSW
NWKEGDDAICLAELKLGFIAQSCLAQGLSTMLANLFSMRSFIKIEEDTWQKYYLEGVSNE
MYTEYLSSAFVGLSFPTVCELCFVKLKLLMIAIEYKSANRESRILINPGNHLKIQEGTLG
FFIASDAKEVKRAFFYCKACHDDITDPKRIKKCGCKRPKMSIYKRMRRACCFDCGRSERD
CSCMSGRVRGNVDTLERAFPLSSVSVNDCSTSFRAFEDEQPSTLSPKKKQRNGGMRNSPN
TSPKLMRHDPLLIPGNDQIDNMDSNVKKYDSTGMFHWCAPKEIEKVILTRSEAAMTVLSG
HVVVCIFGDVSSALIGLRNLVMPLRASNFHYHELKHIVFVGSIEYLKREWETLHNFPKVS
ILPGTPLSRADLRAVNINLCDMCVILSANQNNIDDTSLQDKECILASLNIKSMQFDDSIG
VLQANSQGFTPPGMDRSSPDNSPVHGMLRQPSITTGVNIPIITELVNDTNVQFLDQDDDD
DPDTELYLTQPFACGTAFAVSVLDSLMSATYFNDNILTLIRTLVTGGATPELEALIAEEN
ALRGGYSTPQTLANRDRCRVAQLALLDGPFADLGDGGCYGDLFCKALKTYNMLCFGIYRL
RDAHLSTPSQCTKRYVITNPPYEFELVPTDLIFCLMQFDHNAGQSRASLSHSSHSSQSSS
KKSSSVHSIPSTANRQNRPKSRESRDKQKYVQEERL</protein_sequence>
  </protein_properties>
  <genbank_protein_id>238624130</genbank_protein_id>
  <uniprot_id>Q12791</uniprot_id>
  <uniprot_name>KCMA1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>NM_001161352.1</genbank_gene_id>
  <genecard_id>KCNMA1</genecard_id>
  <geneatlas_id>KCNMA1</geneatlas_id>
  <hgnc_id>HGNC:6284</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Dworetzky SI, Trojnacki JT, Gribkoff VK: Cloning and expression of a human large-conductance calcium-activated potassium channel. Brain Res Mol Brain Res. 1994 Nov;27(1):189-93.</reference_text>
      <pubmed_id>7877450</pubmed_id>
    </reference>
    <reference>
      <reference_text>McCobb DP, Fowler NL, Featherstone T, Lingle CJ, Saito M, Krause JE, Salkoff L: A human calcium-activated potassium channel gene expressed in vascular smooth muscle. Am J Physiol. 1995 Sep;269(3 Pt 2):H767-77.</reference_text>
      <pubmed_id>7573516</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10.  Nature. 2004 May 27;429(6990):375-81.</reference_text>
      <pubmed_id>15164054</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tseng-Crank J, Foster CD, Krause JD, Mertz R, Godinot N, DiChiara TJ, Reinhart PH: Cloning, expression, and distribution of functionally distinct Ca(2+)-activated K+ channel isoforms from human brain. Neuron. 1994 Dec;13(6):1315-30.</reference_text>
      <pubmed_id>7993625</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mazzone JN, Kaiser RA, Buxton IL: Calcium-activated potassium channel expression in human myometrium: effect of pregnancy. Proc West Pharmacol Soc. 2002;45:184-6.</reference_text>
      <pubmed_id>12434576</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pallanck L, Ganetzky B: Cloning and characterization of human and mouse homologs of the Drosophila calcium-activated potassium channel gene, slowpoke. Hum Mol Genet. 1994 Aug;3(8):1239-43.</reference_text>
      <pubmed_id>7987297</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wallner M, Meera P, Ottolia M, Kaczorowski GJ, Latorre R, Garcia ML, Stefani E, Toro L: Characterization of and modulation by a beta-subunit of a human maxi KCa channel cloned from myometrium. Receptors Channels. 1995;3(3):185-99.</reference_text>
      <pubmed_id>8821792</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liu X, Chang Y, Reinhart PH, Sontheimer H, Chang Y: Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells. J Neurosci. 2002 Mar 1;22(5):1840-9.</reference_text>
      <pubmed_id>11880513</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wallner M, Meera P, Toro L: Determinant for beta-subunit regulation in high-conductance voltage-activated and Ca(2+)-sensitive K+ channels: an additional transmembrane region at the N terminus. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14922-7.</reference_text>
      <pubmed_id>8962157</pubmed_id>
    </reference>
    <reference>
      <reference_text>Meera P, Wallner M, Song M, Toro L: Large conductance voltage- and calcium-dependent K+ channel, a distinct member of voltage-dependent ion channels with seven N-terminal transmembrane segments (S0-S6), an extracellular N terminus, and an intracellular (S9-S10) C terminus. Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14066-71.</reference_text>
      <pubmed_id>9391153</pubmed_id>
    </reference>
    <reference>
      <reference_text>Diaz L, Meera P, Amigo J, Stefani E, Alvarez O, Toro L, Latorre R: Role of the S4 segment in a voltage-dependent calcium-sensitive potassium (hSlo) channel. J Biol Chem. 1998 Dec 4;273(49):32430-6.</reference_text>
      <pubmed_id>9829973</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wallner M, Meera P, Toro L: Molecular basis of fast inactivation in voltage and Ca2+-activated K+ channels: a transmembrane beta-subunit homolog. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4137-42.</reference_text>
      <pubmed_id>10097176</pubmed_id>
    </reference>
    <reference>
      <reference_text>Brenner R, Jegla TJ, Wickenden A, Liu Y, Aldrich RW: Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4. J Biol Chem. 2000 Mar 3;275(9):6453-61.</reference_text>
      <pubmed_id>10692449</pubmed_id>
    </reference>
    <reference>
      <reference_text>Quirk JC, Reinhart PH: Identification of a novel tetramerization domain in large conductance K(ca) channels. Neuron. 2001 Oct 11;32(1):13-23.</reference_text>
      <pubmed_id>11604135</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang YW, Ding JP, Xia XM, Lingle CJ: Consequences of the stoichiometry of Slo1 alpha and auxiliary beta subunits on functional properties of large-conductance Ca2+-activated K+ channels. J Neurosci. 2002 Mar 1;22(5):1550-61.</reference_text>
      <pubmed_id>11880485</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tang XD, Xu R, Reynolds MF, Garcia ML, Heinemann SH, Hoshi T: Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels.  Nature. 2003 Oct 2;425(6957):531-5.</reference_text>
      <pubmed_id>14523450</pubmed_id>
    </reference>
    <reference>
      <reference_text>Magleby KL: Gating mechanism of BK (Slo1) channels: so near, yet so far.  J Gen Physiol. 2003 Feb;121(2):81-96.</reference_text>
      <pubmed_id>12566537</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190-203.</reference_text>
      <pubmed_id>18083107</pubmed_id>
    </reference>
    <reference>
      <reference_text>Imami K, Sugiyama N, Kyono Y, Tomita M, Ishihama Y: Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column. Anal Sci. 2008 Jan;24(1):161-6.</reference_text>
      <pubmed_id>18187866</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gordon E, Semus SF, Lozinskaya IM, Lin Z, Xu X: Characterizing the role of Thr352 in the inhibition of the large conductance Ca2+-activated K+ channels by 1-[1-hexyl-6-(methyloxy)-1H-indazol-3-yl]-2-methyl-1-propanone. J Pharmacol Exp Ther. 2010 Aug;334(2):402-9. Epub 2010 Apr 29.</reference_text>
      <pubmed_id>20430843</pubmed_id>
    </reference>
    <reference>
      <reference_text>Du W, Bautista JF, Yang H, Diez-Sampedro A, You SA, Wang L, Kotagal P, Luders HO, Shi J, Cui J, Richerson GB, Wang QK: Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder. Nat Genet. 2005 Jul;37(7):733-8. Epub 2005 Jun 5.</reference_text>
      <pubmed_id>15937479</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Enflurane</name>
        <accession>HMDB14373</accession>
      </metabolite>
      <reference>
        <reference_text>Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K: Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics. Eur J Pharmacol. 2000 Apr 28;395(2):95-101.</reference_text>
        <pubmed_id>10794813</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Enflurane</name>
        <accession>HMDB14373</accession>
      </metabolite>
      <reference>
        <reference_text>Antkowiak B, Kirschfeld K: Enflurane is a potent inhibitor of high conductance Ca(2+)-activated K+ channels of Chara australis. FEBS Lett. 1992 Nov 30;313(3):281-4.</reference_text>
        <pubmed_id>1446749</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF: Chlorzoxazone inhibits contraction of rat thoracic aorta.  Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. Epub 2006 Jun 29.</reference_text>
        <pubmed_id>16859676</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Alvina K, Khodakhah K: KCa channels as therapeutic targets in episodic ataxia type-2.  J Neurosci. 2010 May 26;30(21):7249-57.</reference_text>
        <pubmed_id>20505091</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Syme CA, Gerlach AC, Singh AK, Devor DC: Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels. Am J Physiol Cell Physiol. 2000 Mar;278(3):C570-81.</reference_text>
        <pubmed_id>10712246</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bendroflumethiazide</name>
        <accession>HMDB14580</accession>
      </metabolite>
      <reference>
        <reference_text>Tricarico D, Barbieri M, Mele A, Carbonara G, Camerino DC: Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J. 2004 Apr;18(6):760-1. Epub 2004 Feb 6.</reference_text>
        <pubmed_id>14766795</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cromoglicic acid</name>
        <accession>HMDB15138</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cromoglicic acid</name>
        <accession>HMDB15138</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92.</reference_text>
        <pubmed_id>8760033</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93.</reference_text>
        <pubmed_id>1376313</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Klockner U, Trieschmann U, Isenberg G: Pharmacological modulation of calcium and potassium channels in isolated vascular smooth muscle cells. Arzneimittelforschung. 1989 Jan;39(1A):120-6.</reference_text>
        <pubmed_id>2541731</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>O'Malley D, Shanley LJ, Harvey J: Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-activated K+ channels. Neuropharmacology. 2003 Jun;44(7):855-63.</reference_text>
        <pubmed_id>12726817</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang L, Li X, Zhou R, Xing G: Possible role of potassium channel, big K in etiology of schizophrenia.  Med Hypotheses. 2006;67(1):41-3. Epub 2006 Jan 30.</reference_text>
        <pubmed_id>16446048</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoroacetic acid</name>
        <accession>HMDB14118</accession>
      </metabolite>
      <reference>
        <reference_text>Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K: Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics. Eur J Pharmacol. 2000 Apr 28;395(2):95-101.</reference_text>
        <pubmed_id>10794813</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoroacetic acid</name>
        <accession>HMDB14118</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
